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ABSTRACT 
Temporary interruption of dual antiplatelet therapy (DAPT) is not infrequently required in patients 
undergoing percutaneous coronary intervention (PCI). We sought to describe the procedures and 
outcomes associated with DAPT interruption in patients treated with DAPT following successful PCI 
from the PARIS registry (n=5018). DAPT interruption was pre-specified as physician recommended 
cessation for <14 days. The main endpoints of interest for this analysis were cardiac death, myocardial 
infarction or stent thrombosis occurring subsequent to DAPT interruption. Of the study cohort, 490 
(9.8%) patients experienced 594 DAPT interruptions over 2-years following PCI. Only 1antiplatelet 
agent was interrupted in 57.2% cases and interruption was frequently recommended by non-
cardiologists (51.3%). Where type of surgery was reported, majority of DAPT interruptions occurred for 
minor surgery (68.4% vs. 31.6%) and a similar cessation pattern of single versus dual antiplatelet 
cessation was observed regardless of minor or major surgery. Subsequent to DAPT interruption, 12 
patients (2.4%) patients experienced 1 thrombotic event each, of which 5 (1.0%) occurred during the 
interruption period. All events occurred in patients who stopped both agents (8/12) or clopidogrel-only 
(4/12) with no events occurring due to aspirin cessation alone. In conclusion, in the PARIS registry, 1 in 
10 patients were recommended DAPT interruption for surgery within 2-years of PCI. Interruption was 
more common for a single agent rather than both antiplatelet agents regardless of severity of surgery, 
and was frequently recommended by non-cardiologists. Only 1% of patients with DAPT interruption 
experienced a subsequent thrombotic event during the interruption period, which mainly occurred in 
patients stopping both antiplatelet agents. 
Key words: surgical interruption, dual antiplatelet therapy, percutaneous coronary intervention, major 
adverse cardiac outcomes 
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INTRODUCTION 
Currently, the American College of Cardiology Foundation/ American Heart Association/ Society for 
Cardiovascular Angiography and Interventions (ACCF/AHA/SCAI) percutaneous coronary intervention 
(PCI) guidelines recommend discontinuation of dual antiplatelet therapy (DAPT), with ongoing aspirin if 
possible for surgery and recommencement of a P2Y12 receptor inhibitor as soon as possible in the post-
operative period (Class IIa, C). However, the level of evidence in support of this recommendation is 
scarce, relying mainly on expert consensus[1]. A recent ACC/AHA focused guideline update provides a 
class IB-NR recommendation for DAPT discontinuation prior to elective surgery, at 6 months after drug 
eluting stent (DES) implantation, based on results from the prospective, multicenter observational 
PARIS (Patterns of Non-adherence to Anti-platelet Regiments In Stented Patients) registry[2]. This 
guideline also advises that surgery may be considered between 3-6 months after DES PCI, however, 
surgery should be delayed to beyond 3 months where possible (Class IIb, C-EO)[2]. Therefore, the 
present analysis describes in detail the procedures and outcomes associated with DAPT interruption in 
patients undergoing successful PCI from the PARIS registry [3].  
METHODS 
 The PARIS registry was a multinational registry of 5018 patients enrolled in 15 clinical sites in 
the US and Europe between July 1 2009 and Dec 2 2010 and discharged on DAPT following 
successful PCI [3]. Pre-specified categories of DAPT cessation were physician recommended 
discontinuation, brief interruption (<14 days) or non-recommended disruption. The present study is a 
descriptive analysis of patients enrolled in the PARIS registry who interrupted DAPT within 2 years after 
coronary stent implantation. Major surgery was defined as a surgical procedure requiring general 
anesthesia or hospital admission and was categorized as cardiothoracic, abdomino-pelvic, orthopedic 
or endocrine related surgery. Minor surgery was defined as an out-patient procedure that was 
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performed as a day case and included endoscopy, dental work, biopsy, spinal injections, eye surgery 
and joint injections.  
 The primary endpoint of the main study was 2-year major adverse cardiac events (MACE), 
defined as a composite of cardiac death, spontaneous myocardial infarction (MI), definite/probable 
stent thrombosis or target lesion revascularization[3]. For the present analysis, clinical outcomes of 
interest were individual thrombotic endpoints, cardiac death, spontaneous MI and definite/probable 
stent thrombosis, occurring subsequent to DAPT interruption. Spontaneous MI was defined as 
presence of clinical or electrocardiographic changes consistent with ischemia in the setting of increased 
biomarkers according to the third universal definition. Stent thrombosis was defined as per the 
Academic research consortium criteria. All events were adjudicated by an independent clinical events 
committee following standardized definitions [3].  
 Baseline characteristics are presented in groups of patients with versus without any DAPT 
interruption during 2 years of follow-up. Categorical data are presented as frequencies and compared 
using the chi-squared test. Continuous data are presented as means ± standard deviation (SD) and 
compared using the Student’s t-test. Patterns of interruption and incidence of events rates subsequent 
to interruption were described only in the group with any DAPT interruption. Statistical significance was 
accepted at the 95% confidence level (p <0.05). Statistical analyses were performed using SAS version 
9.2 (Cary, North Carolina, USA).  
RESULTS 
The study cohort comprised 9.8% (n =490) patients experiencing DAPT interruption and 90.2% 
(n =4528) patients without any interruption over 2 years. Tables 1 and 2 show the baseline 
characteristics. There were no differences by age or sex between the groups. Patients with interruption 
had greater prevalence of hypertension, dyslipidemia and prior PCI, but similar prevalence of diabetes 
and lower prevalence of smoking or ACS presentation. Most of the patients experiencing interruption 
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were enrolled in the US rather than Europe. With respect to procedural characteristics, majority of the 
patients in both groups underwent PCI to a single vessel, commonly to the left anterior descending 
artery and nearly three-quarters of patients were treated with second generation DES. Patients with 
interruption were more likely to receive shorter stent lengths with smaller stent diameter, than their 
counterparts without interruption. 
 Over 2 years there were 594 records of DAPT interruptions involving 490 (9.8%) patients, of 
which 206 (4.1%) patients had interruptions in the first year with a peak around 365 days from index 
PCI (Figure 1). Interruptions occurred for both major and minor surgery throughout the follow-up 
period. Overall, minor surgery was more common than major surgery (68.4% vs. 31.6%). Figure 2 
illustrates the specific reasons for surgery in this cohort. Out of 339 (57.1%) cases where the authority 
recommending DAPT interruption was known, interruption was equally recommended by cardiologists 
(48.7%) and non-cardiologists (51.3%) (Figure 3).  
Among all DAPT interruptions, dual antiplatelet cessation occurred in 42.8% (n=254) and single 
antiplatelet agent cessation in 57.2% (n=340) cases, of which clopidogrel-only cessations were more 
frequent (n=192, 32.3%) than aspirin-only cessations (n=148, 24.9%). Where the specific type of 
surgery was known (373 interruptions in 312 patients), single antiplatelet and clopidogrel-only cessation 
was more common regardless of minor or major surgery: 56.9% single agent cessations in minor 
surgery cases  (clopidogrel-only 37.3%, aspirin-only 19.6%) and 56.8% single agent cessations in 
major surgery cases (clopidogrel-only 29.7%, aspirin-only 27.1%).  
 Subsequent to DAPT interruption, 12 (2.4%) unique patients experienced 1 thrombotic event 
each, including 4 cardiac deaths and 8 spontaneous MIs. No patients with DAPT interruption 
experienced definite/probable stent thrombosis. Only 5 events, all MIs, occurred within 2 weeks of 
DAPT interruption; 2 events with major surgery, 2 with minor surgery and in 1 case the type of surgery 
was unknown. These 5 events accounted for 1.0% of all patients and 0.8% of all interruptions. Of these 
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5 events, 4 occurred beyond 1 year from PCI; 2 cases had both antiplatelet agents stopped and 3 
cases had clopiodgrel-only cessation. The remaining 7 events (4 cardiac deaths and 3 MI) occurred 
between day 76 and 725 of DAPT interruption and in all these cases DAPT had been re-initiated, 
therefore being unlikely to be related to interruption itself.  
Overall, 8 of 12 (66.7%) events occurred in patients who stopped both agents, while the 
remaining 4 events occurred in patients who interrupted only clopidogrel. There were no thrombotic 
events in patients with temporary cessation of aspirin alone (Figure 4).  
DISCUSSION 
The current report from the PARIS registry shows the following 1. physician recommended 
temporary DAPT interruption for surgery occurred in approximately 1 in 10 patients over 2 years 
following PCI; 2. single antiplatelet interruptions were more common, whereas both aspirin and P2Y12 
inhibitor interruption occurred in roughly 4 out of 10 patients; 3. the recommendation for DAPT 
interruption was made by cardiologists and non-cardiologists alike and in close to 70% of cases 
interruption was for minor rather than major surgery; 4. DAPT interruptions peaked at 12 months, 
suggesting that both major and minor procedures were generally postponed to beyond the first year 
after PCI; 5. the incidence of adverse outcomes associated with DAPT interruption was extremely low 
and only 1% of patients undergoing interruption for surgery experienced a thrombotic event during the 
interruption period. Moreover, this occurred exclusively in patients who stopped both antiplatelet agents 
or in patients that stopped clopidogrel only. No events occurred in patients who temporarily interrupted 
aspirin alone. No ST events occurred in patients temporarily interrupting DAPT. 
Our rate of DAPT interruption within the first year after PCI, in a cohort predominantly treated 
with 2nd generation DES was 4.1%, in keeping with prior data with rates between 2.5 - 5% [4-6]. Our 
findings are also consistent with previous data that majority of interruptions occur for minor procedures 
including ocular or dental procedures, endoscopies and biopsies [5].  
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With respect to stent selection in patients with planned surgery, PCI frequently results in bare 
metal stent (BMS) implantation, potentially withholding the advantages of 2nd generation DES from 
these patients [7]. Indeed, the current ACCF/AHA/SCAI guidelines recommend balloon angioplasty or 
BMS implantation followed by 4-6 weeks of DAPT in patients requiring elective surgery within 12 
months of PCI (class IIa, B) [1]. This can apply to nearly 16% of PCI patients who may have planned 
surgery within 12 months of stent implantation, as noted from the recent Leaders free trial population 
[8]. However, newer DES with faster endothelialization profiles and shorter DAPT requirements may 
allow DES implantation to be first option in these patients [8].  
 While increased thrombogenicity is inherent to the immediate post-operative period,[9] it is 
unclear whether antiplatelet interruption early after PCI is uniformly detrimental irrespective of factors 
such as stent type and PCI indication. During the early PCI experience with BMS, high rates of death 
and MI were reported in case of surgery within the first 2-5 weeks, and stent thrombosis accounted for 
most of the fatal events[10, 11]. This time frame corresponds to the 4 week period of vascular healing 
after BMS implantation[12]. Subsequent studies with 1st generation DES showed that non-cardiac 
surgery within the first year after stent implantation was an independent predictor of 30-day death, MI 
and revascularization. The EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) registry 
with majority 1st generation DES use, reported a 27-fold increase in composite thrombotic outcomes 
within 7 days of non-cardiac surgery performed in the first year of PCI [6]. Event rates were higher 
when surgery was performed within 6 months of PCI and stabilized thereafter, [13, 14] as a function of 
delayed or incomplete vessel healing due to the effect of anti-proliferative drug or polymer [15-17]. 
Conversely to these data, one study found no significant association between MACE after 
elective non-cardiac surgery and time from PCI with 1st generation DES [18]. Similarly in our cohort, we 
found that 4 out of 5 patients experiencing thrombotic events within 14 days of interruption were >1 
year post-PCI. Further, for events occurring between 76-725 days post interruption, DAPT had been 
reinitiated in all patients, and thus interruption cannot be causatively linked to the thrombotic events. 
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Nevertheless our sample size of patients with interruption was too small to enable definitive conclusions 
for future recommendations.  
Based on recent randomized trial data at least a 6-month period after PCI with 2nd generation 
DES may be advisable before recommending interruption for surgery[19, 20]. Although prolonged 
DAPT has been shown to decrease the risk of stent thrombosis, this is at the expense of higher 
bleeding[21]. Moreover, shorter DAPT durations may not be associated with greater risk of stent 
thrombosis in patients receiving new-generation DES[22]. Further data are needed to understand the 
safety of early interruption with the use of these stents. 
 Contrary to the ACCF/AHA/SCAI guidelines, which recommend aspirin continuation through the 
peri-operative period[23], we found that over 40% patients stopped both anti-platelet agents regardless 
of major or minor surgery. This discordance between guidelines and practice reflects the conflicting 
clinical evidence for the optimal perioperative regimen. Large multicenter cohort studies have shown 
that complete interruption of anti-platelet therapy earlier than 5 days before surgery[24] and re-initiation 
later than 48 hours after coronary artery bypass surgery [25] increased the risk of ischemic events. A 
systematic review and meta-analysis including 8 randomized controlled trials and 15 observational 
studies showed that pre-operative aspirin increased post-operative bleeding in PCI patients, but this 
could potentially be avoided by the use of aspirin doses <325 mg/day[26]. In a small RCT, Oscarsson 
et al. demonstrated that in high-risk patients undergoing non-cardiac surgery, perioperative low dose 
aspirin continued to the third postoperative day, reduced the risk of MACE without increasing 
bleeding[27]. Conversely, the POISE-2 RCT refuted the benefits of continued peri-operative aspirin 
against increased the risk of major bleeding. However less than one-third of POISE-2 trial patients had 
a history of coronary artery disease and only 5% had prior PCI[28].  
Our findings of a 1% rate of thrombotic events in patients interrupting DAPT, suggests that 
DAPT interruption for surgery is not a tremendous concern following contemporary PCI. Further, since 
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adverse events were limited to patients stopping either clopidogrel or both antiplatelet drugs prior to 
surgery, aspirin-only interruption could be considered as a suitable option. Notwithstanding, with the 
availability of newer stents and the use of potent P2Y12 therapies in PCI, future studies are needed to 
re-examine these associations. Physician recommended interruption should continue to be tailored to 
individual patient ischemic and bleeding risks. 
 This present study is limited by its observational nature, relatively small sample size of patients 
with DAPT interruption, particularly within the first 6 months of PCI, and small number of events. 
However these data are derived from an all-comer international multicenter PCI population, reflecting 
the patterns in managing patients treated with second generation DES. Our rates of interruption for 
surgery are similar to reports from other international cohorts, supporting the findings of this analysis [4-
6].  These data are drawn from patients treated with aspirin and clopidogrel and do not apply to the use 
of potent P2Y12 therapies. We did not collect specific information on post-surgery bleeding. In the 
absence of stent thrombosis, it may be inferred that MI events were non-stent related and might include 
causes such as Takotsubo cardiomyopathy, which has been observed post surgery [29].  
In conclusion, 1 in 10 patients are recommended DAPT interruption for surgery within 2 years of 
PCI. Interruption is more common for single rather than dual antiplatelet agent cessation, regardless of 
major or minor surgery and is uniformly recommended by cardiologists and non-cardiologists. Only 1% 
of patients with physician recommended DAPT interruption experienced a thrombotic event during the 
interruption period, which mainly occurred in patients who stopped both antiplatelet agents. 
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Figure legends 
Figure 1: Frequency of interruption over the follow up period. 
Figure 2: Types of surgical procedures requiring dual antiplatelet treatment interruption  
Figure 3: Recommending sources for dual antiplatelet treatment interruption by physician 
specialty 
Figure 4: Withdrawal patterns of antiplatelet agents in DAPT interruption patients experiencing 
thrombotic events. 
DAPT, dual antiplatelet therapy 
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Table 1. Baseline characteristics 
 Interruption of DAPT Treatment  
Variable 
Yes 
(N = 490) 
No  
(N = 4528) 
p-value 
Age (years), mean ± SD 65.24 ± 10.71 63.56 ± 11.40 0.99 
Women 133 (27.1%) 1146 (25.3%) 0.38 
Body mass index (kg/m 2), mean ± SD 30.06 ± 5.66 29.18 ± 5.63 0.99 
Dyslipidemia requiring medication 396(80.7%) 3405 (75.2%) 0.006 
Hypertension requiring medication 422(85.9%) 3587 (79.2%) <0.0001 
Family History of Coronary Artery Disease 179(36.5%) 1427 (31.5%) 0.024 
Current Smoker 74(15.1%) 907 (20.0%) 0.009 
Diabetes Mellitus 176(35.8%) 1478 (32.6%) 0.14 
Previous Myocardial Infarction 130(26.5%) 1084 (23.9%) 0.20 
Previous Percutaneous Coronary Intervention 229 (46.7%) 1741 (38.5%) <0.0001 
Previous Coronary Artery Bypass Surgery 75(15.3%) 610 (13.5%) 0.26 
Stroke  19(3.9%) 154 (3.4%) 0.58 
Transient Ischemia Attack 14(2.9%) 123 (2.7%) 0.86 
Peripheral Vascular Disease 41(8.4%) 351 (7.8%) 0.63 
CARDIAC STATUS AT ADMISSION    
 Silent Myocardial Ischemia 46(9.4%) 476 (10.6%) 0.44 
 Stable Angina Pectoris 270(55.0%) 2168 (47.9%) 0.002 
 Acute Coronary Syndrome 174(35.4%) 1882 (41.6%) 0.01 
 REGION   <0.0001 
 Europe 20(1.5%) 1338 (98.5%)  
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 Interruption of DAPT Treatment  
Variable 
Yes 
(N = 490) 
No  
(N = 4528) 
p-value 
 United States 470(12.8%) 3190 (87.2%)  
DISCHARGE MEDICATIONS    
  Thienopyridine type   0.022 
 Clopidogrel 458(93.3%) 4177 (92.3%)  
 Prasugrel 32(6.5%) 282 (6.2%)  
  Warfarin 31(6.3%) 283 (6.3%) 0.95 
  Proton Pump Inhibitor 117(23.9%) 1057 (23.3%) 0.79 
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Table 2. Procedural characteristics 
 Interruption of DAPT Treatment  
Variable 
Yes 
(N = 490) 
No  
(N = 4528) 
p-value 
Narrowed coronary artery    
 Left Main 12(2.4%) 146 (3.2%) 0.35 
 Left anterior descending  226(46.0%) 2098 (46.3%) 0.93 
 Proximal left anterior descending 102(20.8%) 1015 (22.4%) 0.42 
 Left circumflex 158(32.2%) 1392 (30.7%) 0.49 
 Right  167(34.0%) 1593 (35.2%) 0.63 
 Number of narrowed coronary arteries   0.90 
 1 422(85.9%) 3870 (85.5%)  
 2 63(12.8%) 615 (13.6%)  
 3 5(1.0%) 43 (0.9%)  
 Bifurcation lesion 42(8.6%) 553 (12.2%) 0.018 
 Chronic total occlusion 20(4.1%) 172 (3.8%) 0.76 
 Thrombotic lesion 25(5.1%) 390 (8.6%) 0.007 
Stent type   0.72 
 Bare metal stent 89(18.1%) 726 (16.0%)  
 Drug eluting stent, 1st generation 67(13.6%) 607 (13.4%)  
 Drug eluting stent, 2nd generation 365(74.3%) 3195 (70.6%)  
 Number of stents implanted   0.003 
 1 301(61.3%) 2481 (54.8%)  
 2 106(21.6%) 1309 (28.9%)  
 >2 83(16.9%) 738 (16.3%)  
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 Interruption of DAPT Treatment  
Variable 
Yes 
(N = 490) 
No  
(N = 4528) 
p-value 
 Total stented length (mm)   0.012 
 ≤20  213(43.4%) 1706 (37.7%)  
 >20  277(56.4%) 2822 (62.3%)  
Maximum stent diameter (mm), mean ± SD 3.06 ± 0.48 3.12 ± 0.50 0.0044 
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